/
LIVN
$83.06-$0.37 (-0.44%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.6B
55M shares
52-week range
$41.02 – $83.98
98% from low
Sector
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Exchange
NASDAQ
CS
Borrow rate
0.25%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2.21
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.11B | $1.08B | $934.2M | $1.04B | $1.02B | $1.15B | $1.25B | $1.39B |
| Cost of revenue | $372.5M | $360.4M | $339.5M | $329.4M | $314.6M | $382.3M | $382.6M | $448.2M |
| Gross profit | $734.5M | $723.8M | $594.8M | $706.0M | $707.2M | $771.3M | $870.9M | $939.9M |
| Gross margin | 66.4% | 66.8% | 63.7% | 68.2% | 69.2% | 66.9% | 69.5% | 67.7% |
| R&D | $146.0M | $197.1M | $152.9M | $183.4M | $155.8M | $193.8M | $182.5M | $185.8M |
| Operating income | −$248.1M | −$171.6M | −$273.9M | −$784.0K | −$76.8M | −$68.5M | $129.1M | $199.4M |
| EBITDA | −$167.7M | $119.2M | $6.3M | −$6.3M | $30.9M | $38.5M | $202.5M | −$129.5M |
| Net income | −$189.4M | −$157.6M | −$348.8M | −$135.8M | −$86.2M | $17.5M | $63.2M | −$242.5M |
| Net margin | -17.1% | -14.5% | -37.3% | -13.1% | -8.4% | 1.5% | 5.0% | -17.5% |
| EPS (diluted) | -3.91 | -3.22 | -7.06 | -2.68 | -1.61 | 0.32 | 1.16 | -4.45 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $1.5B | $4.25 | $4.24–$4.26 | 6 |
| 2027 | $1.6B | $4.63 | $4.50–$4.91 | 6 |
| 2028 | $1.7B | $5.09 | $4.78–$5.37 | 4 |
| 2029 | $2.1B | $7.10 | $6.96–$7.27 | 2 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
LivaNova PLC Ordinary Shares
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
www.livanova.com- Employees
- 3,300
- IPO / List date
- Feb 10, 1993
- HQ
- LONDON, X0
Held by traders on TradeandTell
No one on the platform currently holds LIVN.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in LIVN as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded LIVN yet.
